RxDoctor Payments Data

Perrie Ryan, MD

Hematology & Oncology · West Columbia, SCNPI 1073530432

Payments from drug & device makers

$5,563in general payments, 2019–2025

Across 258 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$594
  • Bristol Myers Squibb$429
  • Johnson & Johnson$345
  • Pfizer$298
  • E.r. Squibb & Sons, L.L.C.$287
  • AstraZeneca$272
  • plus $3K from 53 others

What the payments were for

  • Food & beverage$5,52099%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis25$594
Bristol Myers Squibb23$429
Johnson & Johnson10$345
Pfizer17$298
E.r. Squibb & Sons, L.L.C.20$287
AstraZeneca(2 entities)15$272
Daiichi Sankyo Inc.12$267
Merck10$216
Amgen5$210
Genentech USA, Inc.11$195
Galvanize Therapeutics, Inc1$169
Tempus AI, Inc3$151
Gilead(2 entities)7$146
AbbVie6$118
Lilly USA, LLC6$109
Bayer4$106
Sanofi4$105
Sobi, Inc5$97
Regeneron Healthcare Solutions, Inc.4$87
Incyte Corporation4$76
Karyopharm Therapeutics Inc.3$74
Eisai Inc.3$63
Astellas Pharma US Inc3$60
Takeda Pharmaceuticals U.S.A., Inc.3$58
Seagen Inc.3$58
Boehringer Ingelheim2$55
EMD Serono, Inc.3$50
Taiho Oncology, Inc.2$47
AVEO Pharmaceuticals, Inc.2$44
Dova Pharmaceuticals3$44
Acrotech Biopharma Inc.2$43
Beigene USA, Inc.2$41
Pharmaessentia USA Corporation2$40
Beone Medicines USA, Inc.2$39
Pharmacosmos Therapeutics Inc.1$38
Pharmacyclics LLC, An Abbvie Company2$35
GSK2$33
Array Biopharma Inc2$32
Kyowa Kirin, Inc.2$31
Iovance Biotherapeutics, Inc.1$29
Puma Biotechnology, Inc.2$29
Springworks Therapeutics, Inc.2$29
Celltrion USA Inc.1$24
Ipsen Biopharmaceuticals, Inc1$23
Tersera Therapeutics LLC1$22
Accord Healthcare, Inc.1$21
Cycle Pharmaceuticals Inc1$21
Blueprint Medicines Corporation1$20
Servier Pharmaceuticals LLC1$20
ADC Therapeutics America, Inc.1$19
Teva Pharmaceuticals USA, Inc.1$19
Sun Pharmaceutical Industries Inc.1$18
Spectrum Pharmaceuticals Inc.1$18
Partner Therapeutics, Inc.1$17
Jazz Pharmaceuticals Inc.1$16
Deciphera Pharmaceuticals Inc.1$15
Exelixis Inc.1$14
Mirati Therapeutics, Inc.1$14
Immunocore Limited1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,563 in reported general payments places this provider in the 40th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$5,970,801
Medicare patients
1,183
Services billed
266,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide74$900,626
RevlimidLenalidomide33$539,088
Abiraterone Acetate137$400,713
InlytaAxitinib22$342,691
Lenalidomide29$323,243
SprycelDasatinib20$254,482
LynparzaOlaparib14$215,576
JakafiRuxolitinib Phosphate12$207,556
OrgovyxRelugolix12$32,537
EliquisApixaban11$5,972
Ondansetron OdtOndansetron89$1,701
Hydroxyurea54$1,438
Prednisone190$1,374
Prochlorperazine Maleate100$1,279
Bicalutamide53$1,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$60$900,62674 claims
Bristol Myers SquibbRevlimid$429$539,08833 claims
PfizerInlyta, Eliquis$298$348,66333 claims
E.r. Squibb & Sons, L.L.C.Sprycel$287$254,48220 claims
AstraZenecaLynparza$272$215,57614 claims
Incyte CorporationJakafi$76$207,55612 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$19$38424 claims
Lilly USA, LLCOlanzapine$109$17435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 166 hematology & oncology providers in South Carolina.

Other hematology & oncology in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →